{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:53:53Z","timestamp":1773687233321,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40744-021-00335-7","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T10:02:38Z","timestamp":1625392958000},"page":"1241-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study"],"prefix":"10.1007","volume":"8","author":[{"given":"Elise","family":"Doar\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Robin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Racap\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Le M\u00e9l\u00e9do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Orione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Guggenbuhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Dernis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Bouvard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Marhadour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,4]]},"reference":[{"issue":"2","key":"335_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.rdc.2006.03.002","volume":"32","author":"H Choi","year":"2006","unstructured":"Choi H. Epidemiology of crystal arthropathy. Rheum Dis Clin North Am. 2006;32(2):255\u201373. https:\/\/doi.org\/10.1016\/j.rdc.2006.03.002 (v).","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"335_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"335_CR3","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, FitzGerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout part II: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361. https:\/\/doi.org\/10.1002\/acr.21773.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"335_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jbspin.2020.05.001","volume":"87","author":"A Latourte","year":"2020","unstructured":"Latourte A, Pascart T, Flipo R-M, et al. 2020 Recommendations from the French Society of Rheumatology for the management of gout: management of acute flares. Joint Bone Spine. 2020;87(5):387\u201393. https:\/\/doi.org\/10.1016\/j.jbspin.2020.05.001.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"335_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O\u2019Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155\u201363. https:\/\/doi.org\/10.1016\/j.amjmed.2010.09.012.","journal-title":"Am J Med"},{"issue":"7081","key":"335_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341. https:\/\/doi.org\/10.1038\/nature04516.","journal-title":"Nature"},{"issue":"2","key":"335_CR7","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar3297","volume":"13","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13(2):R53. https:\/\/doi.org\/10.1186\/ar3297.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"335_CR8","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar4303","volume":"15","author":"S Ottaviani","year":"2013","unstructured":"Ottaviani S, Molt\u00f3 A, Ea H-K, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. https:\/\/doi.org\/10.1186\/ar4303.","journal-title":"Arthritis Res Ther"},{"key":"335_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/357826","author":"EAS Nunes","year":"2014","unstructured":"Nunes EAS, Rosseti AG, Ribeiro DS, Santiago M. Gout initially mimicking rheumatoid arthritis and later cervical spine involvement. Case Rep Rheumatol. 2014. https:\/\/doi.org\/10.1155\/2014\/357826.","journal-title":"Case Rep Rheumatol"},{"issue":"10","key":"335_CR10","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/art.39254","volume":"67","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol Hoboken NJ. 2015;67(10):2557\u201368. https:\/\/doi.org\/10.1002\/art.39254.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"8","key":"335_CR11","first-page":"1511","volume":"33","author":"V Devauchelle-Pensec","year":"2006","unstructured":"Devauchelle-Pensec V, Berthelot JM, Jousse S, et al. Performance of hand radiographs in predicting the diagnosis in patients with early arthritis. J Rheumatol. 2006;33(8):1511\u20135.","journal-title":"J Rheumatol"},{"issue":"8","key":"335_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.7326\/M18-1167","volume":"169","author":"DH Solomon","year":"2018","unstructured":"Solomon DH, Glynn RJ, MacFadyen JG, et al. Relationship of interleukin-1\u03b2 blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535\u201342. https:\/\/doi.org\/10.7326\/M18-1167.","journal-title":"Ann Intern Med"},{"key":"335_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.05.002","author":"T Pascart","year":"2020","unstructured":"Pascart T, Latourte A, Flipo R-M, et al. recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine. 2020. https:\/\/doi.org\/10.1016\/j.jbspin.2020.05.002.","journal-title":"Joint Bone Spine"},{"issue":"7","key":"335_CR14","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/ard.2010.144063","volume":"70","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, Mysler E, Lin H-Y, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264\u201371. https:\/\/doi.org\/10.1136\/ard.2010.144063.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"335_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jbspin.2018.03.015","volume":"85","author":"C Loustau","year":"2018","unstructured":"Loustau C, Rosine N, Forien M, et al. Effectiveness and safety of anakinra in gout patients with stage 4\u20135 chronic kidney disease or kidney transplantation: a multicentre, retrospective study. Joint Bone Spine. 2018;85(6):755\u201360. https:\/\/doi.org\/10.1016\/j.jbspin.2018.03.015.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"335_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","volume":"74","author":"B-B Yang","year":"2003","unstructured":"Yang B-B, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74(1):85\u201394. https:\/\/doi.org\/10.1016\/S0009-9236(03)00094-8.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"335_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057352","volume":"8","author":"H-K Ea","year":"2013","unstructured":"Ea H-K, Chobaz V, Nguyen C, et al. Pathogenic role of basic calcium phosphate crystals in destructive arthropathies. PLoS ONE. 2013;8(2): e57352. https:\/\/doi.org\/10.1371\/journal.pone.0057352.","journal-title":"PLoS ONE"},{"issue":"2","key":"335_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1526-4637.2004.04022.x","volume":"5","author":"S Omoigui","year":"2004","unstructured":"Omoigui S, Irene S. Subcutaneous injection of anakinra in patients with shoulder pain due to rotator cuff tendonitis and subacromial bursitis. Pain Med Malden Mass. 2004;5(2):229\u201330. https:\/\/doi.org\/10.1111\/j.1526-4637.2004.04022.x.","journal-title":"Pain Med Malden Mass"},{"issue":"11","key":"335_CR19","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839\u201348. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200908.","journal-title":"Ann Rheum Dis"},{"key":"335_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key402","author":"CA Janssen","year":"2019","unstructured":"Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al. Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatol Oxf Engl. 2019. https:\/\/doi.org\/10.1093\/rheumatology\/key402.","journal-title":"Rheumatol Oxf Engl"},{"issue":"5","key":"335_CR21","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","volume":"2","author":"V Kl\u00fcck","year":"2020","unstructured":"Kl\u00fcck V, Jansen TLTA, Janssen M, et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020;2(5):e270\u201380. https:\/\/doi.org\/10.1016\/S2665-9913(20)30065-5.","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"335_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ard.2010.139360","volume":"70","author":"W Zhang","year":"2011","unstructured":"Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70(4):571\u20135. https:\/\/doi.org\/10.1136\/ard.2010.139360.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"335_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jbspin.2012.07.018","volume":"80","author":"S Ottaviani","year":"2013","unstructured":"Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013;80(2):178\u201382. https:\/\/doi.org\/10.1016\/j.jbspin.2012.07.018.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"335_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10067-018-4272-2","volume":"38","author":"M Thomas","year":"2019","unstructured":"Thomas M, Forien M, Palazzo E, Dieud\u00e9 P, Ottaviani S. Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases. Clin Rheumatol. 2019;38(2):425\u201330. https:\/\/doi.org\/10.1007\/s10067-018-4272-2.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"335_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3899\/jrheum.181018","volume":"46","author":"JW Liew","year":"2019","unstructured":"Liew JW, Gardner GC. Use of anakinra in hospitalized patients with crystal-associated arthritis. J Rheumatol. 2019;46(10):1345\u20139. https:\/\/doi.org\/10.3899\/jrheum.181018.","journal-title":"J Rheumatol"},{"issue":"12","key":"335_CR26","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/rheumatology\/kez203","volume":"58","author":"T Pascart","year":"2019","unstructured":"Pascart T, Norberciak L, Ea H-K, Graf S, Guggenbuhl P, Liot\u00e9 F. Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Rheumatol Oxf Engl. 2019;58(12):2181\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kez203.","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"335_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/acr.22660","volume":"68","author":"T Bardin","year":"2016","unstructured":"Bardin T, Bou\u00e9e S, Clerson P, et al. Prevalence of gout in the adult population of France. Arthritis Care Res. 2016;68(2):261\u20136. https:\/\/doi.org\/10.1002\/acr.22660.","journal-title":"Arthritis Care Res"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-021-00335-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T08:13:43Z","timestamp":1629620023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-021-00335-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00335-7","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,4]]},"assertion":[{"value":"14 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}